Last reviewed · How we verify
Allograft
At a glance
| Generic name | Allograft |
|---|---|
| Also known as | Mineralized corticocancellous allograft |
| Sponsor | King Abdulaziz University |
| Modality | Biologic |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- A Modified Platform Trial of Multiple CAMPs for the Management of Diabetic Foot Ulcers and Venous Leg Ulcers (NA)
- Syk Inhibition in MItigating Lung Allograft Rejection (SIMILAR): A Trial to Evaluate the Safety and Tolerability of Fostamatinib in Lung Transplant Patients With Donor-Specific Antibodies (PHASE1)
- Using Different Biomaterials to Preserve Bone After Tooth Extraction (NA)
- Tocilizumab in Lung Transplantation (PHASE2)
- Improved Methods of Cell Selection for Bone Marrow Transplant Alternatives
- A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction (PHASE3)
- AlloSure Lung Assessment and Metagenomics Outcomes Study
- Allograft vs. Autograft Nonunion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Allograft CI brief — competitive landscape report
- Allograft updates RSS · CI watch RSS
- King Abdulaziz University portfolio CI